Ensysce Biosciences, Inc. Logo

Ensysce Biosciences, Inc.

Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.

ENSC | US

Overview

Corporate Details

ISIN(s):
US2936021086 (+2 more)
LEI:
Country:
United States of America
Address:
7946 IVANHOE AVENUE, 92037 LA JOLLA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company dedicated to developing safer prescription drugs for severe pain to address the opioid epidemic. The company utilizes its proprietary technology platforms, Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®), to create novel opioids with built-in abuse deterrence and overdose protection. The TAAP™ platform creates prodrugs that are activated only in the gastrointestinal tract, minimizing abuse via non-oral routes. The MPAR® system is designed to prevent overdose by limiting drug activation when excessive doses are consumed. The company's lead product candidate, PF614, has received 'Fast Track' and 'Breakthrough Therapy' designations from the FDA.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ensysce Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ensysce Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ensysce Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan 4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan 4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB

Talk to a Data Expert

Have a question? We'll get back to you promptly.